Coagulation factor IX, GlycoPEGylated (Rebinyn): Difference between revisions
No edit summary |
No edit summary |
||
Line 313: | Line 313: | ||
(Description) | (Description) | ||
|howSupplied=( | |howSupplied=*REBINYN is supplied in packages comprised of a single-use vial containing nominally 500, 1000, or 2000 IU of Factor IX potency; a MixPro ® pre-filled diluent syringe containing 10 mM histidine solution (1.6 mg/mL), and a sterile vial adapter with 25 micrometer filter, which serves as a needleless reconstitution device. | ||
|storage=( | |||
*The actual Factor IX potency in IU is stated on each REBINYN carton and vial. | |||
[[image:Coagulation_factor_IX,_GlycoPEGylated_(Rebinyn)_How_Supplied_Table.png|none|thumb|400px|This image is provided by the National Library of Medicine.]] | |||
*The REBINYN vials are made of glass, closed with a chlorobutyl rubber stopper (not made with natural rubber latex), and sealed with an aluminum cap. | |||
*The pre-filled diluent syringes are made of glass, with a siliconised bromobutyl rubber plunger (not made with rubber latex). | |||
*The closed vials and pre-filled diluent syringes are equipped with a tamper-evident snap-off cap which is made of polypropylene. | |||
|storage=*Store REBINYN in the original package in order to protect from light. | |||
*Store REBINYN under refrigeration at a temperature of 36°F-46°F (2°C – 8°C) for up to 24 months from the date of manufacture until the expiration date stated on the label. | |||
*REBINYN may be stored at room temperature not to exceed 86°F (30°C) for up to 6 months within the 24-month time period. Record the date when the product was removed from the refrigerator in the space provided on the outer carton. The total time of storage at room temperature should not exceed 6 months. Do not return the product to the refrigerator. | |||
*Do not use REBINYN after the end of the 6-month period at room temperature storage, or after the expiration date stated on the vial, whichever occurs earlier. | |||
*Do not freeze REBINYN. | |||
*Use REBINYN within 4 hours after reconstitution when stored at room temperature. Store the reconstituted product in the vial. | |||
*Discard any unused reconstituted product stored at room temperature for more than 4 hours. | |||
|packLabel=[[image:Coagulation_factor_IX,_GlycoPEGylated_(Rebinyn)_Package_Label_1.jpeg|none|thumb|400px|This image is provided by the National Library of Medicine.]] | |packLabel=[[image:Coagulation_factor_IX,_GlycoPEGylated_(Rebinyn)_Package_Label_1.jpeg|none|thumb|400px|This image is provided by the National Library of Medicine.]] | ||
Revision as of 03:50, 27 July 2018
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Yashasvi Aryaputra[2];
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Black Box Warning
Warning Title
See full prescribing information for complete Boxed Warning.
Condition Name: (Content)
|
Overview
Coagulation factor IX, GlycoPEGylated (Rebinyn) is a Acetylcholine release inhibitor, Adrenergic receptor agonist that is FDA approved for the (type of indication of drug) of a list of indications, separated by commas.. There is a Black Box Warning for this drug as shown here. Common adverse reactions include a list of adverse reactions, separated by commas..
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
Condition 1
- Dosing Information
- (Dosage)
Condition 2
- Dosing Information
- (Dosage)
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
Condition 1
- Developed by: (Organisation)
- Class of Recommendation: (Class) (Link)
- Strength of Evidence: (Category A/B/C) (Link)
- Dosing Information/Recommendation
- (Dosage)
Condition 2
- Developed by: (Organisation)
- Class of Recommendation: (Class) (Link)
- Strength of Evidence: (Category A/B/C) (Link)
- Dosing Information/Recommendation
- (Dosage)
Non–Guideline-Supported Use
Condition 1
- Dosing Information
- (Dosage)
Condition 2
- Dosing Information
- (Dosage)
Condition 3
- Dosing Information
- (Dosage)
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
Condition 1
- Dosing Information
- (Dosage)
Condition 2
- Dosing Information
- (Dosage)
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
Condition 1
- Developed by: (Organisation)
- Class of Recommendation: (Class) (Link)
- Strength of Evidence: (Category A/B/C) (Link)
- Dosing Information/Recommendation
- (Dosage)
Condition 2
- Developed by: (Organisation)
- Class of Recommendation: (Class) (Link)
- Strength of Evidence: (Category A/B/C) (Link)
- Dosing Information/Recommendation
- (Dosage)
Non–Guideline-Supported Use
Condition 1
- Dosing Information
- (Dosage)
Condition 2
- Dosing Information
- (Dosage)
Condition 3
- Dosing Information
- (Dosage)
Contraindications
CONTRAINDICATIONS
Warnings
Warning Title
See full prescribing information for complete Boxed Warning.
Condition Name: (Content)
|
Conidition 1
(Description)
Conidition 2
(Description)
Conidition 3
(Description)
Adverse Reactions
Clinical Trials Experience
Central Nervous System
- (list/description of adverse reactions)
Cardiovascular
- (list/description of adverse reactions)
Respiratory
- (list/description of adverse reactions)
Gastrointestinal
- (list/description of adverse reactions)
Hypersensitive Reactions
- (list/description of adverse reactions)
Miscellaneous
- (list/description of adverse reactions)
Condition 2
Central Nervous System
- (list/description of adverse reactions)
Cardiovascular
- (list/description of adverse reactions)
Respiratory
- (list/description of adverse reactions)
Gastrointestinal
- (list/description of adverse reactions)
Hypersensitive Reactions
- (list/description of adverse reactions)
Miscellaneous
- (list/description of adverse reactions)
Postmarketing Experience
(Description)
Drug Interactions
- Drug 1
- Drug 2
- Drug 3
- Drug 4
- Drug 5
Drug 1
(Description)
Drug 2
(Description)
Drug 3
(Description)
Drug 4
(Description)
Drug 5
(Description)
Use in Specific Populations
Pregnancy
Pregnancy Category (FDA):
(Description)
Pregnancy Category (AUS):
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Coagulation factor IX, GlycoPEGylated (Rebinyn) in women who are pregnant.
Labor and Delivery
(Description)
Nursing Mothers
(Description)g
Pediatric Use
(Description)
Geriatic Use
(Description)
Gender
(Description)
Race
(Description)
Renal Impairment
(Description)
Hepatic Impairment
(Description)
Females of Reproductive Potential and Males
(Description)
Immunocompromised Patients
(Description)
Others
(Description)
Administration and Monitoring
Administration
(Oral/Intravenous/etc)
Monitoring
Condition 1
(Description regarding monitoring, from Warnings section)
Condition 2
(Description regarding monitoring, from Warnings section)
Condition 3
(Description regarding monitoring, from Warnings section)
IV Compatibility
There is limited information regarding the compatibility of Coagulation factor IX, GlycoPEGylated (Rebinyn) and IV administrations.
Overdosage
Acute Overdose
Signs and Symptoms
(Description)
Management
(Description)
Chronic Overdose
Signs and Symptoms
(Description)
Management
(Description)
Pharmacology
Coagulation factor IX, GlycoPEGylated (Rebinyn)
| |
Systematic (IUPAC) name | |
? | |
Identifiers | |
CAS number | ? |
ATC code | ? |
PubChem | ? |
Chemical data | |
Formula | ? |
Mol. mass | ? |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Mechanism of Action
(Description)
Structure
(Description with picture)
Pharmacodynamics
(Description)
Pharmacokinetics
(Description)
Nonclinical Toxicology
(Description)
Clinical Studies
Condition 1
(Description)
Condition 2
(Description)
Condition 3
(Description)
How Supplied
- REBINYN is supplied in packages comprised of a single-use vial containing nominally 500, 1000, or 2000 IU of Factor IX potency; a MixPro ® pre-filled diluent syringe containing 10 mM histidine solution (1.6 mg/mL), and a sterile vial adapter with 25 micrometer filter, which serves as a needleless reconstitution device.
- The actual Factor IX potency in IU is stated on each REBINYN carton and vial.
![](/images/4/4d/Coagulation_factor_IX%2C_GlycoPEGylated_%28Rebinyn%29_How_Supplied_Table.png)
- The REBINYN vials are made of glass, closed with a chlorobutyl rubber stopper (not made with natural rubber latex), and sealed with an aluminum cap.
- The pre-filled diluent syringes are made of glass, with a siliconised bromobutyl rubber plunger (not made with rubber latex).
- The closed vials and pre-filled diluent syringes are equipped with a tamper-evident snap-off cap which is made of polypropylene.
Storage
- Store REBINYN in the original package in order to protect from light.
- Store REBINYN under refrigeration at a temperature of 36°F-46°F (2°C – 8°C) for up to 24 months from the date of manufacture until the expiration date stated on the label.
- REBINYN may be stored at room temperature not to exceed 86°F (30°C) for up to 6 months within the 24-month time period. Record the date when the product was removed from the refrigerator in the space provided on the outer carton. The total time of storage at room temperature should not exceed 6 months. Do not return the product to the refrigerator.
- Do not use REBINYN after the end of the 6-month period at room temperature storage, or after the expiration date stated on the vial, whichever occurs earlier.
- Do not freeze REBINYN.
- Use REBINYN within 4 hours after reconstitution when stored at room temperature. Store the reconstituted product in the vial.
- Discard any unused reconstituted product stored at room temperature for more than 4 hours.
Images
Drug Images
{{#ask: Page Name::Coagulation factor IX, GlycoPEGylated (Rebinyn) |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
![](/images/8/8f/Coagulation_factor_IX%2C_GlycoPEGylated_%28Rebinyn%29_Package_Label_1.jpeg)
![](/images/8/88/Coagulation_factor_IX%2C_GlycoPEGylated_%28Rebinyn%29_Package_Label_2.jpeg)
![](/images/0/04/Coagulation_factor_IX%2C_GlycoPEGylated_%28Rebinyn%29_Package_Label_3.jpeg)
![](/images/e/ea/Coagulation_factor_IX%2C_GlycoPEGylated_%28Rebinyn%29_Package_Label_4.jpeg)
![](/images/a/a7/Coagulation_factor_IX%2C_GlycoPEGylated_%28Rebinyn%29_Package_Label_5.jpeg)
![](/images/4/4e/Coagulation_factor_IX%2C_GlycoPEGylated_%28Rebinyn%29_Package_Label_6.jpeg)
![](/images/f/f7/Coagulation_factor_IX%2C_GlycoPEGylated_%28Rebinyn%29_Package_Label_7.jpeg)
{{#ask: Label Page::Coagulation factor IX, GlycoPEGylated (Rebinyn) |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
- Inform patients of the early signs of hypersensitivity reactions including rash, hives, itching, facial swelling, tightness of the chest and wheezing. Advise patients to discontinue use of the product and contact their healthcare provider if these symptoms occur.
- Advise patients to contact their healthcare provider for further treatment and/or assessment if they experience a lack of a clinical response to Factor IX therapy, as in some cases this may be a manifestation of an inhibitor.
- Advise patients to contact their healthcare provider if they experience any thrombotic complications.
- Advise patients to follow the recommendations regarding proper sharps disposal provided in the FDA-approved Instructions for Use.
Precautions with Alcohol
Alcohol-Coagulation factor IX, GlycoPEGylated (Rebinyn) interaction has not been established. Talk to your doctor regarding the effects of taking alcohol with this medication.
Brand Names
- Rebinyn
Look-Alike Drug Names
There is limited information regarding Coagulation factor IX, GlycoPEGylated (Rebinyn) Look-Alike Drug Names in the drug label.
Drug Shortage Status
Drug Shortage
Price
References
The contents of this FDA label are provided by the National Library of Medicine.